

Belgium


Treatment at diagnosis by country

Global enrolment of Prospective patients


Region	n	%
Europe	29167	56
Asia	14988	28.8
North America	1618	3.1
Latin America	4247	8.2
Rest of World	2061	4
Total	52081	100




Treatment at diagnosis by country



Treatment at diagnosis by region



Treatment at diagnosis by cohort



Baseline characteristics

		Belgium N=(1713)	World N=(52081)
Sex	Female, n (%)	722 (42.1)	23015 (44.2)
Age at Diagnosis (Years)	mean (sd)	71.3 (10.8)	69.7 (11.5)
Age Group	<65, n (%)	407 (23.8)	15716 (30.2)
	65-74, n (%)	569 (33.2)	16956 (32.6)
	>=75, n (%)	737 (43.0)	19409 (37.3)
BMI (kg/m ²)	mean (sd)	28.8 (5.7)	27.8 (5.7)
Pulse (bpm)	mean (sd)	97.5 (30.4)	90.4 (26.7)
Systolic BP (mm Hg)	mean (sd)	136.2 (21.4)	133.5 (19.8)
Diastolic BP (mm Hg)	mean (sd)	80.7 (13.4)	79.7 (12.9)
Congestive heart failure	n (%)	209 (12.2)	10405 (20.0)
Coronary artery disease	n (%)	290 (16.9)	11251 (21.6)
Acute coronary syndrome	n (%)	151 (8.8)	4914 (9.5)
Carotid Occlusive Disease	n (%)	47 (2.8)	1546 (3.0)
Cirrhosis	n (%)	7 (0.4)	296 (0.6)

Baseline characteristics

		Belgium N=(1713)	World N=(52081)
Diabetes	n (%)	282 (16.5)	11550 (22.2)
History of Bleeding	n (%)	47 (2.7)	1320 (2.5)
Hypercholesterolaemia	n (%)	936 (55.7)	20975 (41.6)
PE or DVT	n (%)	41 (2.4)	1356 (2.6)
Stroke/TIA	n (%)	170 (9.9)	5961 (11.4)
Treatment Sector	In the private sector, n (%)	417 (24.4)	12547 (28.5)
	In the public sector, n (%)	1290 (75.6)	31431 (71.5)

Baseline characteristics

		Belgium N=(1713)	World N=(52081)
CHADS2 Score	mean (sd)	1.7 (1.1)	1.9 (1.1)
CHA2DS2-VASc Score	mean (sd)	3.1 (1.5)	3.2 (1.6)
HAS BLED Score	mean (sd)	1.5 (0.9)	1.4 (0.9)

Baseline characteristics

		Belgium N=(1713)	World N=(52081)
Systemic Embolization	n (%)	16 (0.9)	336 (0.6)
Type of AF Diagnosed	New, n (%)	877 (51.2)	23366 (44.9)
	Paroxysmal, n (%)	447 (26.1)	14313 (27.5)
	Permanent, n (%)	44 (2.6)	6639 (12.7)
Care Setting Speciality at Diagnosis	Persistent, n (%)	345 (20.1)	7761 (14.9)
	Cardiology, n (%)	1492 (87.1)	34219 (65.7)
	Geriatrics, n (%)	11 (0.6)	202 (0.4)
	Internal Medicine, n (%)	56 (3.3)	9372 (18.0)
	Neurology, n (%)	23 (1.3)	876 (1.7)
	Primary Care/General Practice, n (%)	131 (7.6)	7410 (14.2)


Main reason anticoagulant not used for patients with CHA₂DS₂-VASc ≥2 .

	Cohort 1&2			
	Belgium		World	
	(N=33)	(N=4137)	(N=4137)	(N=4137)
	n	%	n	%
Patients with CHA ₂ DS ₂ -VASc ≥2 and no AC treatment at diagnosis				
Alcohol abuse			20	(0.5)
Already taking anti-platelet drugs for other medical condition	2	(6.1)	228	(5.5)
Patient refusal	3	(9.1)	336	(8.1)
Previous bleeding event			63	(1.5)
Taking medication contraindicated or cautioned for use with VKA or AC	1	(3.0)	19	(0.5)
Other	3	(9.1)	505	(12.2)
Unknown	7	(21.2)	889	(21.5)
Physician's choice	17	(51.5)	2077	(50.2)
Physician's choice - Bleeding risk	2	(6.1)	263	(6.4)
Physician's choice - Concern over patient compliance			182	(4.4)
Physician's choice - Guideline recommendation	5	(15.2)	105	(2.5)
Physician's choice - Fall risk	2	(6.1)	197	(4.8)
Physician's choice - Low risk of stroke	1	(3.0)	326	(7.9)
Physician's choice - Other	7	(21.2)	1004	(24.3)
Total	33	(100.0)	4137	(100.0)


Main reason anticoagulant not used for patients with $\text{CHA}_2\text{DS}_2\text{-VASc} \geq 2$.

	Cohort 3&4&5			
	Belgium		World	
	(N=51)	(N=6117)	(N=6117)	(N=6117)
	n	%	n	%
Patients with $\text{CHA}_2\text{DS}_2\text{-VASc} \geq 2$ and no AC treatment at diagnosis				
Alcohol abuse			32	(0.5)
Already taking anti-platelet drugs for other medical condition	2	(3.9)	422	(6.9)
Patient refusal	1	(2.0)	645	(10.5)
Previous bleeding event	3	(5.9)	151	(2.5)
Taking medication contraindicated or cautioned for use with VKA or AC	1	(2.0)	63	(1.0)
Other	12	(23.5)	1326	(21.7)
Unknown	9	(17.6)	1597	(26.1)
Physician's choice	23	(45.1)	1881	(30.8)
Physician's choice - Bleeding risk	6	(11.8)	611	(10.0)
Physician's choice - Concern over patient compliance			248	(4.1)
Physician's choice - Guideline recommendation	3	(5.9)	189	(3.1)
Physician's choice - Fall risk	1	(2.0)	205	(3.4)
Physician's choice - Low risk of stroke	13	(25.5)	628	(10.3)
Total	51	(100.0)	6117	(100.0)


Stroke risk profile: CHADS₂



Stroke risk profile: CHA₂DS₂ VASc



Stroke risk profile: HAS BLED




Treatment at diagnosis by CHA2DS2-VASc score - Belgium

CHA2DS2-VASc		VKA±AP	FXa±AP	DTI±AP	AP	None	Unknown	Total
		n	n	n	n	n	n	n
Belgium	Unknown	9	12	6	5	7	0	39
	0	7	13	9	16	18	3	66
	1	48	59	16	39	34	1	197
	2	49	174	54	32	35	0	344
	3	46	236	60	26	33	4	405
	4	36	214	75	34	19	0	378
	5	30	87	35	20	7	2	181
	6-9	21	54	12	10	5	1	103


Treatment at diagnosis by CHA₂DS₂-VASc score - World

CHA ₂ DS ₂ -VASc		VKA±AP	FXa±AP	DTI±AP	AP	None	Unknown	Total
		n	n	n	n	n	n	n
World	Unknown	461	227	62	286	330	14	1380
	0	325	221	111	302	443	16	1418
	1	1830	1097	479	1545	1196	66	6213
	2	3835	1960	806	2154	1261	125	10141
	3	4969	2625	817	2345	1275	164	12195
	4	4711	2352	772	2043	1028	168	11074
	5	2458	1169	375	1224	449	98	5773
	6-9	1616	831	234	872	261	73	3887

Treatment at diagnosis



Treatment at diagnosis




Treatment at diagnosis by HAS BLED score - Belgium

HASBLED		VKA±AP	FXa±AP	DTI±AP	AP	None	Unknown	Total	
		n	n	n	n	n	n	N	n
Belgium	Unknown	85	261	127	74	57	3	607	607
	0	36	49	13	0	35	1	134	134
	1	58	276	56	38	40	4	472	472
	2	36	188	53	50	20	2	349	349
	3	23	65	16	17	6	1	128	128
	4-9	8	10	2	3	0	0	23	23


Treatment at diagnosis by HAS BLED score - World

HASBLED		VKA±AP	FXa±AP	DTI±AP	AP	None	Unknown	Total
		n	n	n	n	n	n	n
World	Unknown	5750	2456	843	3271	2060	147	14527
	0	2144	1242	611	0	1394	96	5487
	1	6650	3866	1303	2302	1779	254	16154
	2	4165	2225	689	3689	763	163	11694
	3	1258	599	191	1250	219	53	3570
	4-9	238	94	19	259	28	11	649

Treatment at diagnosis



Treatment at diagnosis



INR values and time in therapeutic range

Variable	Statistics	Belgium (N = 246) n %	World (N = 20205) n %
INR value, n(%)	n (missing)	1472 (133)	157134 (8319)
	<2	539 (36.6)	50514 (32.1)
	2-3	632 (42.9)	81056 (51.6)
	>3	301 (20.4)	25564 (16.3)
INR value	n (missing)	1472 (133)	157134 (8319)
	Mean (SD)	2.4 (1.0)	2.4 (0.9)
	Median (IQR)	2.2 (1.7 to 2.9)	2.3 (1.8 to 2.8)
	Min to Max	0.9 to 10.0	0.8 to 20.0
TTR, n(%)	n (missing)	113 (133)	11485 (8720)
	<65	85 (75.2)	6734 (58.6)
	>=65	28 (24.8)	4751 (41.4)
TTR	Median (IQR)	47.2 (29.2 to 62.4)	59.0 (37.0 to 76.1)
	Min to Max	0.0 to 100.0	0.0 to 100.0
	n (missing)	113 (133)	11485 (8720)
	Mean (SD)	46.1 (23.8)	55.2 (27.3)

Event rates during the first year of follow-up (rates per 100 person-years)

	Belgium		World	
	Events	Rate (95% CI)	Events	Rate (95% CI)
Death	75	4.57 (3.64 to 5.73)	2103	4.38 (4.20 to 4.57)
Cardiovascular Death	21	1.28 (0.83 to 1.96)	789	1.64 (1.53 to 1.76)
Non-cardiovascular death	41	2.50 (1.84 to 3.39)	771	1.61 (1.50 to 1.72)
Undetermined Cause	13	0.79 (0.46 to 1.36)	543	1.13 (1.04 to 1.23)
Stroke/SE	17	1.04 (0.65 to 1.67)	650	1.36 (1.26 to 1.47)
Major Bleeding	23	1.41 (0.94 to 2.12)	407	0.85 (0.77 to 0.94)
Acute coronary syndrome	12	0.73 (0.42 to 1.29)	378	0.79 (0.71 to 0.87)
Congestive hearth failure	29	1.78 (1.24 to 2.57)	1052	2.22 (2.09 to 2.35)

Cause of death during the first year of follow-up

	Belgium		World	
	n	%	n	%
Cardiovascular causes				
Congestive heart failure	6	28.6	262	33.2
Sudden or unwitnessed death	5	23.8	127	16.1
Myocardial infarction	3	14.3	89	11.3
Non-haemorrhagic stroke (Ischemic Stroke)	2	9.5	86	10.9
Non Cardiovascular causes				
Malignancy	7	17.1	233	30.2
Respiratory failure	10	24.4	142	18.4
Infection	6	14.6	81	10.5
Sepsis	4	9.8	74	9.6

Type of stroke during the first year of follow-up

	Belgium		World	
	n	%	n	%
Stroke (not including systemic embolism)	13	0.76	585	1.12
Primary Ischemic	10	0.58	406	0.78
of which secondary hemorrhagic ischemic	1	0.06	22	0.04
Primary intracerebral hemorrhage	1	0.06	71	0.14
Intracerebral	1	0.06	44	0.08
Intraventricular			9	0.02
Subarachnoid			13	0.02
Undetermined	2	0.12	108	0.21

Severity of bleeding during the first year of follow-up

Outcome	Belgium		World	
	n	%	n	%
Major Bleed	23	0.04	407	0.78
Non-Major Clinically Relevant	50	0.10	645	1.24
Minor	63	0.12	1167	2.24
Unknown	2	0.00	136	0.26